Marengo Therapeutics

Private

#Oncology #Immuno-oncology #Solid Tumors #Autoimmune

Clinical-stage immuno-oncology company pioneering precision T cell activator and engager antibodies that selectively target non-clonal V-beta TCR subsets to mount durable anti-tumor responses in patients resistant to checkpoint inhibition.

Company Info

Sector:Biotechnology / Immuno-oncology

Headquarters:Cambridge, Massachusetts, USA

Founded:2015

Website:marengotx.com/

Funding Round:Series C

Total Funding:~$80M

Funding & Investor Relations

Notable Investors

Apple Tree Partners

Upcoming Milestones & Key Dates

2026-10-15

Regulatory

Second FDA Fast Track designation for invikafusp alfa in tissue-agnostic TMB-high solid tumors

Clinical Development Pipeline

Invikafusp alfa (STAR0602)

Target: V-beta6/10 T cell agonist (dual T cell activation)

Checkpoint-inhibitor-resistant TMB-high solid tumors (STARt-001)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Invikafusp alfa + sacituzumab govitecan

Target: V-beta6/10 T cell agonist plus TROP2 ADC (Gilead collaboration)

Triple-negative and HR+/HER2- breast cancer (STARt-002)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TriSTAR0701

Target: Nectin-4 trispecific T cell engager

Bladder and other Nectin-4-expressing cancers

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

Clinical Regulatory•Oct 15, 2026•PR Newswire FDA

Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition ↗

Marengo Therapeutics received a second FDA Fast Track designation for invikafusp alfa, expanding to a tissue-agnostic indication in TMB-high solid tumors that progressed after prior therapy, including checkpoint inhibition.

Leadership Team

Zhen Su

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Careers

Cambridge, Massachusetts, USA

Apply Now →